Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)

NASHVILLE, Tenn., May 18 /PRNewswire/ -- Cumberland Pharmaceuticals announced
today the launch of an online in-service program for hospitals using Acetadote
(acetylcysteine) Injection, the company's intravenous treatment for
acetaminophen overdose.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090518/CL18638 )

Available at www.acetadote.net, the webcast provides hospital pharmacists and
physicians, educators and other healthcare providers with information and
guidelines on dosage and administration of Acetadote for treatment of
acetaminophen poisoning. The webcast is designed to supplement and reinforce
information provided by Cumberland's hospital sales force through convenient,
anytime access to training. This online program will also provide detailed
training to hospitals where personal in-service visits by a Cumberland
representative are not readily available.

"We are pleased to offer this additional level of support for healthcare
providers using our product," said A.J. Kazimi, CEO of Cumberland
Pharmaceuticals. "Acetadote is a potentially life-saving drug, and as use of
the product continues to rise we believe it is important to provide healthcare
professionals with as much information as possible to facilitate proper
administration."

About Acetadote
Acetadote is used in the emergency department and hospital inpatient setting
to prevent or lessen potential liver damage resulting from an overdose of
acetaminophen, a common ingredient in many over-the-counter and prescription
medications. It is the only approved injectable product in the United States
for the treatment of acetaminophen overdose, the leading cause of toxic drug
ingestions reported to U.S. poison control centers(1).

Acetadote is contraindicated in patients with hypersensitivity or previous
anaphylactoid reactions to acetylcysteine or any components of the
preparation. Serious anaphylactoid reactions, including death in a patient
with asthma, have been reported in patients administered acetylcysteine
intravenously. Acetadote should be used with caution in patients with asthma,
or where there is a history of bronchospasm. The total volume administered
should be adjusted for patients less than 40 kg and for those requiring fluid
restriction. To avoid fluid overload, the volume of diluent should be reduced
as needed. If volume is not adjusted, fluid overload can occur, potentially
resulting in hyponatremia, seizure, and death.

Please visit www.acetadote.net for the full prescribing information.

About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical
company that develops and markets niche pharmaceutical products for specific
physician segments, including hospital acute care and gastroenterology.
Cumberland is dedicated to providing high-quality products which fill unmet
medical needs. For more information, please visit the Cumberland
Pharmaceuticals web site at www.cumberlandpharma.com.

Forward-Looking Statements
This release contains forward-looking statements which reflect management's
current views of future events and operations. Forward-looking statements
involve certain significant risks and uncertainties, and actual results may
differ materially from these statements. Cumberland does not undertake to
publicly update or revise any of its forward-looking statements even if
experience or future changes show that the indicated results or events will
not be realized.

(1) National Poison Data System, American Association of Poison Control
Centers

Acetadote(R) is a registered trademark of Cumberland Pharmaceuticals Inc.

SOURCE Cumberland Pharmaceuticals

Rebecca Kirkham, Lovell Communications, +1-615-297-7766